Notably, overexpression of PRAME has been observed in malignant melanoma (88% of primary lesions and 95% of metastases), lung carcinoma (46% of adenocarcinomas and 78% of squamous cell carcinomas), renal cell carcinoma, neuroblastoma, myxoid liposarcoma, and synovial sarcoma15,18–22. Here, PRAME is linked to myxoid liposarcoma.